

Applicants : Riccardo Dalla-Favera  
Serial No. : 09/724,254  
Filed : November 28, 2000  
Page 14

In response, applicant has hereinabove amended the specification to properly identify the sequences by SEQ ID NO. where necessary. A marked-up copy of the amended paragraphs is annexed hereto as **Exhibit 1**. Applicant has also amended the claims to properly identify the sequences by SEQ ID NO. where necessary. A marked-up copy of the amended claims is annexed hereto as **Exhibit 2**. The amendments are merely to insert SEQ ID NOs. into the application and to correct certain minor grammatical errors. Applicant maintains that the amendments to the specification and claims raise no issue of new matter. Accordingly, applicant respectfully requests that this Amendment be entered.

Further, applicant annexes hereto a corrected paper form of the Sequence Listing as **Exhibit A**, a Computer Readable Form of the corrected Sequence Listing, and a Statement in Accordance with 37 C.F.R. §1.821(f) as **Exhibit B**.

Applicant maintains that in view of this Amendment, this application satisfies the requirements of 37 C.F.R. §§1.821-1.825.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicant's undersigned attorneys invite the Examiner to telephone them at the number provided below.


Applicants : Riccardo Dalla-Favera  
Serial No. : 09/724,254  
Filed : November 28, 2000  
Page 15

No fee, other than the \$55.00 extension fee, is deemed necessary in connection with the filing of this Amendment. If any fee is required however, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White  
Registration No. 28,678  
Alan J. Morrison  
Registration No. 37,399  
Attorneys for Applicant  
Cooper & Dunham LLP  
1185 Avenue of the Americas  
New York, New York 10036  
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents BOX SEQUENCE P.O. Box 2327 Arlington, VA 22202	
 Alan J. Morrison Reg. No. 37,399	5/23/02 Date

Marked-Up Copy Of The Amendments To The Specification

The paragraph starting on page 6, line 16 has been amended as follows:

--This invention provides an isolated nucleic acid molecule comprising at least 15 contiguous nucleotides capable of specifically hybridizing with a unique sequence included within the sequence of the isolated nucleic acid molecule encoding IRTA protein. In an embodiment, the IRTA protein may be IRTA1, IRTA2, IRTA3, IRTA4 or IRTA5 protein, or fragment(s) thereof, having the amino acid sequence set forth in any of Figures 18A (SEQ ID NO:1), 18B-1-18B-3 (SEQ ID NOs:3, 41, 44), 18C-1-18C-2 (SEQ ID NO:5), 18D-1-18D-2 (SEQ ID NO:7) or 18E-1-18E-2 (SEQ ID NO:9), respectively.--

The paragraph starting on page 7, line 23 has been amended as follows:

--This invention provides a purified IRTA2 protein comprising an [the] amino acid sequence set forth in Figures 18B-1-18B-3 (SEQ ID NO:41, SEQ ID NO:3, SEQ ID NO:44).--

The paragraph starting on page 11, line 2 has been amended as follows:

--**Figures 1A-1B.** Molecular cloning of the translocation t(1;14)(q21;q32) in the FR4 multiple myeloma cell line. Fig. 1A) Schematic representation of the  $\lambda$ FR4B-5 and  $\lambda$ FR4S-a clones, representing der(14) and der(1) breakpoints, and of the germline IgH and 1q21 loci. Fig. 1B) Nucleotide sequence

of the breakpoint junction (SEQ ID NO:12) and its alignment to the corresponding germline regions of chromosome 14 (SEQ ID NO:13). Chr 1 is SEQ ID NO:11. S $\alpha$ , IgA switch region; LCR: 3' IgH locus control region; B, *Bam*HI; H, *Hind*III; X, *Xho*I.--

The paragraph starting on page 16, line 24 has been amended as follows:

--**Figure 5.**

Nucleotide and amino acid sequence of human MUM2 (SEQ ID NO:14 and SEQ ID NO:15, respectively). The deduced amino acid sequence is shown above the nucleotide sequence in one-letter code and is numbered on the right, with position 1 set to the first codon of the signal peptide. The predicted signal peptidase site was derived by a computer algorithm described in Nielsen et al., Protein Engineering 10, 1-6 (1997) and is marked by an arrowhead. The polyadenylation signal AATAAA is underlined. Potential sites for N-glycosylation are also underlined in the amino acid sequence. A hydrophobic stretch of 16 amino acids predicted to span the plasma membrane is doubly underlined. Consensus SH2-binding sites are highlighted by a wavy underline.--

The paragraph starting on page 17, line 11 has been amended as follows:

--Figure 6A. Nucleotide and amino acid sequence of human MUM3-a (SEQ ID NO:16 and SEQ ID NO:17, respectively). The deduced amino acid sequence is shown above the nucleotide sequence in one-letter code and is numbered on the right, with position 1 set to the first codon of the signal peptide. The predicted site for signal peptidase cleavage was derived as previously stated above and is marked by an arrowhead. The polyadenylation signal ATTAAA is underlined. Potential sites for N-glycosylation are also underlined in the amino acid sequence. The protein lacks a transmembrane domain and is predicted to be secreted.--

The paragraph starting on page 17, line 26 has been amended as follows:

--Figure 6B. Nucleotide and amino acid sequence of human MUM3-b (SEQ ID NO:18 and SEQ ID NO:19, respectively). The deduced amino acid sequence is shown above the nucleotide sequence in one-letter code and is numbered on the right, with position 1 set to the first codon of the signal peptide. The predicted site for signal peptidase cleavage was derived as previously stated above and is marked by an arrowhead. The polyadenylation signal AATAAA is underlined. Potential sites for N-glycosylation are underlined in the amino acid sequence.--

The paragraph starting on page 18, line 7 has been amended as follows:

--Figure 6C-1-6C-2. Nucleotide and amino acid sequence of human MUM3-c (SEQ ID NO:20 and SEQ ID NO:21, respectively). The deduced amino acid sequence is shown above the nucleotide sequence in one-letter code and is numbered on the right, with position 1 set to the first codon of the signal peptide. The predicted site for signal peptidase cleavage was derived as previously stated above and is marked by an arrowhead. The polyadenylation signal AATAAA is underlined. Potential sites for N-glycosylation are underlined in the amino acid sequence. A hydrophobic stretch of 23 amino acids predicted to span the plasma membrane is doubly underlined. Consensus SH2-binding sites are highlighted by a wavy underline.--

The paragraph starting on page 18, line 27 has been amended as follows:

--Figures 7A-7C. t(1;14)(q21;32) in FR4 generates a MUM2/Ca fusion transcript. (Fig. 7A) Schematic representation of the der(14) genomic clone  $\lambda$ FR4B-5 and of the germline IgHA1 locus. The FR4 breakpoint is marked by an arrow. Filled and open boxes represent the MUM2 and Calpha coding and non-coding exons respectively.

The position of the MUM2 exon 1 probe used for Northern blot analysis is shown by a bar. (Fig. 7B) Northern blot analysis with a MUM2 exon 1 probe on FR4 and additional cell lines detects an abnormal message of 0.8 Kb, selectively in FR4. Arrowheads point to the location of normal MUM2 message in EREB mRNA. JJN3 and U266, myeloma cell lines; EREB, conditional EBV-transformed B lymphoblastoid cell line. Two  $\mu$ g of polyA<sup>+</sup> RNA were loaded per lane. (Fig. 7C) Nucleotide [ans] and amino acid sequence of the MUM2-Ca fusion cDNA in FR4 (SEQ ID NO:23 and SEQ ID NO:22, respectively). The cDNA was amplified by RT-PCR from FR4 total RNA using the primers shown in Fig. 7A, and was subsequently subcloned and sequenced. The deduced amino acid sequence is shown above the nucleotide sequence in one-letter code and is numbered on the right with position 1 set to the first codon of the signal peptide. The predicted site for signal peptidase cleavage was derived as previously stated above and is marked by an arrowhead. The polyadenylation signal AATAAA is underlined. The Calpha transmembrane domain is underlined. The MUM2 portion of the cDNA is shown on italics. H, HindIII; B, BamHI; X, XhoI; S $\alpha$ , IgA switch region; EC, extracellular region; TM, transmembrane; CYT,

cytoplasmic domain.--

The paragraph starting on page 20, line 4 has been amended as follows:

--**Figures 8A-8C.** Molecular cloning of the translocation t(1;14)(q21;q32) in the FR4 multiple myeloma cell line. (Fig. 8A) Schematic representation of the phage clones representing der(14) and der(1) breakpoints and the germline IGH and 1q21 loci. Chromosome 14 sequences are indicated by a solid black line with black boxes representing *Ca1* exons. Chromosome 1 sequences are shown as a grey line. The probes used for chromosomal mapping are indicated below the map. Restriction enzyme codes are: B, *Bam*HI; H, *Hind*III; X, *Xho*I; S, *Sac*I; E, *Eco*RI. For enzymes marked by (\*) only sites delineating the probes are shown. Sa: IgA switch region; LCR: 3' IgH locus control region. (Fig. 8B) Nucleotide sequence of the breakpoint junctions (SEQ ID NO:25 and SEQ ID NO:27). and their alignment to the corresponding germline regions of chromosomes 14 and 1 (SEQ ID NO:24 and SEQ ID NO:26, respectively). (Fig. 8C) Left, fluorescence in situ hybridization (FISH) analysis on human normal metaphase spreads with the PAC clone 49A16 (Fig. 13) spanning the germline1q21 region at the FR4



breakpoint. Right, DAPI stained image from the same metaphase spread.--

The paragraph starting on page 21, line 27 has been amended as follows:

--**Figures 10A-10B.** Comparison of the amino acid sequences of IRTA1 (SEQ ID NO:32) and IRTA2 (SEQ ID NO:33) with members of the Fc Receptor family (Fig. 10A) Multiple sequence alignment of the first two (top) and the third (bottom) extracellular Ig-domains of IRTA1 and IRTA2 to Fc receptor family members; FCGRIIA (SEQ ID NO:28), FCGRIIIA (SEQ ID NO:29), FCERIA (SEQ ID NO:30), and FCGR1A (SEQ ID NO:31). The sequences were compared using the ClustalW program (Thompson et al., 1994). Black-shaded boxes indicate conserved aminoacids among all sequences; dark-grey shaded boxes indicate conserved aminoacids among at least half of the sequences; light-shaded boxes indicate conservative substitutions. (Fig. 10B) Alignment of the SH2-binding domains of IRTA1 (SEQ ID NO:35) and IRTA2 (SEQ ID NO:37) with the ITAM (SEQ ID NO:34) and ITIM (SEQ ID NO:39) consensus motifs. Conserved [aminoacid] amino acid positions are in bold. BGP is SEQ ID NO:38 and PECAM is SEQ ID NO:36. Symbol X represents any [aminoacid] amino acid.--

The paragraph starting on page 27, line 30 has been amended as follows:

--Figure 18A. IRTA1 cDNA (SEQ ID NO:2) and the amino acid sequence (SEQ ID NO:1) of the encoded IRTA1 protein.--

The paragraph starting on page 28, line 1 has been amended as follows:

--Figures 18B-1-18B-3. IRTA2 cDNA (2a, SEQ ID NO:43; 2b, SEQ ID NO:4; 2c, SEQ ID NO:40) and the amino acid sequence (2a, SEQ ID NO:44; 2b, SEQ ID NO:3; 2c, SEQ ID NO:41) of the encoded IRTA2 protein.--

The paragraph starting on page 28, line 5 has been amended as follows:

--Figures 18C-1-18C-2. IRTA3 cDNA (SEQ ID NO:6) and the amino acid sequence (SEQ ID NO:5) of the encoded IRTA3 protein.--

The paragraph starting on page 28, line 9 has been amended as follows:

--Figures 18D-1-18D-2. IRTA4 cDNA (SEQ ID NO:8) and the amino acid sequence (SEQ ID NO:7) of the encoded IRTA4 protein.--

The paragraph starting on page 28, line 13 has been amended as follows:

--**Figures 18E-1-18E-2.** IRTA5 cDNA (SEQ ID NO:10) and the amino acid sequence (SEQ ID NO:9) of the encoded IRTA5 protein.--

The paragraph starting on page 30, line 4 has been amended as follows:

--In another embodiment of the above-described isolated nucleic acid molecule, the encoded IRTA protein is IRTA2 protein comprising the amino acid sequence set forth in Figures 18B-1-18B-3 (SEQ ID NO:44; SEQ ID NO:3; SEQ ID NO:41).--

The paragraph starting on page 30, line 24 has been amended as follows:

--In another embodiment of any of the above-described isolated nucleic acid molecules, the nucleic acid molecule is DNA. In further embodiments, the DNA is cDNA. In additional embodiments, the DNA is genomic DNA. In another embodiment, the nucleic acid molecule is an RNA molecule. In yet another embodiment, the DNA molecule is cDNA having the nucleotide sequence set forth in Figure 18A (SEQ ID NO:2). In another embodiment, the DNA molecule is cDNA having the nucleotide sequence set forth in Figure [18A] 18B (SEQ ID NO:43; SEQ ID NO:4; SEQ ID NO:40). In a further embodiment, the DNA molecule is cDNA having the nucleotide sequence set forth in Figure [18A] 18C (SEQ ID NO:6). In another embodiment, the DNA molecule is cDNA having the nucleotide sequence set forth in Figure [18A] 18D (SEQ ID NO:8). In an embodiment, the DNA molecule is cDNA having the nucleotide sequence set forth in Figure [18A] 18E (SEQ ID NO:10). In preferred embodiments of the isolated nucleic acid molecule, wherein the nucleic acid

molecules encode human IRTA1, IRTA2, IRTA3, IRTA4 or IRTA5 protein. In additional embodiments, the nucleic acid molecules encode mammalian IRTA1 protein. The mammalian IRTA1 protein may be murine IRTA1 protein. In another preferred embodiment, the isolated nucleic acid molecules are operatively linked to a promoter of DNA transcription. In yet another preferred embodiment of the isolated nucleic acid molecule, the promoter comprises a bacterial, yeast, insect, plant or mammalian promoter.--

The paragraph starting on page 39, line 31 has been amended as follows:

--This invention provides a purified IRTA2 protein comprising the amino acid sequence set forth in Figures 18B-1-18B-3 (SEQ ID NO:44; SEQ ID NO:3; SEQ ID NO:41). In an embodiment of the purified IRTA2 protein, the IRTA2 protein is human IRTA2.--

The paragraph starting on page 63, line 28 has been amended as follows:

--Sequence analysis of the breakpoint regions on the derivative chromosomes and alignment with the germline 14q32 and 1q21 loci revealed that the breakpoint had occurred in the intron between the CH3 and the transmembrane exon of  $C\alpha_1$  on chromosome 14. Although the breakpoint region was devoid of recombination signal sequences (RSS) or switch signal sequences (Kuppers et al., 1999), the sequence CTTAAC (underlined on Figure 8B) was present in both germline chromosomes 14 and 1 at the breakpoint junction. One copy of this sequence was present in each of the derivative chromosomes, with a slight modification in the der(1) copy (point mutation in the last nucleotide: C to G). The

nucleotides AT preceding CTTAAC on chromosome 1 were also present in both derivative chromosomes (Figure 8B). The translocation did not result in any loss of chromosome 1 sequences. On the other hand, in the chromosome 14 portion of der(1) we observed two deletions upstream of the breakpoint junction: a 16 nucleotide deletion (GGCACCTCCCCTTAAC) (SEQ ID NO:42) and a 4 nucleotide deletion (TGCA) 6 nucleotides upstream (Figure 8B). These observations indicate that the t(1;14)(q21;q32) in FR4 cells represents a balanced reciprocal translocation possibly facilitated by the presence of homologous sequences (CTTAAC) on both chromosomes.--

Marked-Up Copy Of Amendments To Claims

Claims 3, 12-15 and 35 have been amended as follows:

- 3. (Amended)The isolated nucleic acid molecule of claim 1, wherein the IRTA protein is an IRTA2 protein comprising [the] an amino acid sequence set forth in [Figures 18B-1-18B-3 (SEQ ID NO:3)] SEQ ID NO:3, SEQ ID NO:41 or SEQ ID NO:44.--
- 12. (Amended)The isolated DNA molecule of claim 2, wherein the DNA molecule is cDNA having [the] a nucleotide sequence set forth in [Figure 18A (SEQ ID NO:4)] SEQ ID NO:4, SEQ ID NO:40 or SEQ ID NO:43.--
- 13. (Amended)The isolated DNA molecule of claim 2, wherein the DNA molecule is cDNA having the nucleotide sequence set forth in Figure [18A] 18C (SEQ ID NO:6).--
- 14. (Amended)The isolated DNA molecule of claim 2, wherein the DNA molecule is cDNA having the nucleotide sequence set forth in Figure [18A] 18D (SEQ ID NO:8).--
- 15. (Amended)The isolated DNA molecule of claim 2, wherein the DNA molecule is cDNA having the nucleotide sequence set forth in Figure [18A] 18E (SEQ ID NO:10).--
- 35. (Amended)A purified IRTA2 protein comprising an [the] amino acid sequence set forth in [Figures 18B-1-18B-3 (SEQ ID NO:3)] SEQ ID NO:3, SEQ ID NO:41 or SEQ ID NO:44.--